Theravance Biopharma, Inc. Deferred Revenue Recognized
Theravance Biopharma, Inc. (TBPH) reported Deferred Revenue Recognized of $31.25 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-27.
Discontinued › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2020-02-27
- Theravance Biopharma, Inc. contract with customer, liability, revenue recognized for the quarter ending 2019-09-30 was $8.84M, a 126128.57% increase year-over-year.
- Theravance Biopharma, Inc. contract with customer, liability, revenue recognized for the quarter ending 2019-06-30 was $7.49M, a 46725.00% increase year-over-year.
- Theravance Biopharma, Inc. contract with customer, liability, revenue recognized for the quarter ending 2019-03-31 was $5.33M, a 33231.25% increase year-over-year.
- Theravance Biopharma, Inc. contract with customer, liability, revenue recognized for the quarter ending 2018-09-30 was $7.00K.
- Theravance Biopharma, Inc. contract with customer, liability, revenue recognized for fiscal 2019 was $31.25M, a 23934.62% increase from fiscal 2018.
- Theravance Biopharma, Inc. contract with customer, liability, revenue recognized for fiscal 2018 was $130.00K.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2019-12-31 | $31.25M 10-K · filed 2020-02-27 | |||
| 2019-09-30 | $8.84M 10-Q · filed 2019-11-08 | $21.66M 10-Q · filed 2019-11-08 | ||
| 2019-06-30 | $7.49M 10-Q · filed 2019-08-05 | $12.82M 10-Q · filed 2019-08-05 | ||
| 2019-03-31 | $5.33M 10-Q · filed 2019-05-10 | |||
| 2018-12-31 | $130.00K 10-K · filed 2020-02-27 | |||
| 2018-09-30 | $7.00K 10-Q · filed 2019-11-08 | $39.00K 10-Q · filed 2019-11-08 | ||
| 2018-06-30 | $16.00K 10-Q · filed 2019-08-05 | $32.00K 10-Q · filed 2019-08-05 | ||
| 2018-03-31 | $16.00K 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |